New drops first to treat cause and symptoms of dry eye

Article

Patients with keratoconjunctivitis sicca (or dry eye) now have a therapeutic option that both relieves symptoms and treats the underlying disease. The FDA recently approved cyclosporine (Restasis, Allergan) 0.5% ophthalmic emulsion to increase tear production in patients whose tear production is believed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. The company expects to launch Restasis in early April.

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Related Content
© 2025 MJH Life Sciences

All rights reserved.